Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.
Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.
Citron analyst sees 'indestructible moat' around genetic-testing company's business.
Another day, another busy earnings day! What to watch on Wednesday, July 31, 2019.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.